Senseonics Holdings, Inc. Common Stock (SENS) - Net Assets
Based on the latest financial reports, Senseonics Holdings, Inc. Common Stock (SENS) has net assets worth $78.17 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($139.92 Million) and total liabilities ($61.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SENS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $78.17 Million |
| % of Total Assets | 55.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44621.77 |
Senseonics Holdings, Inc. Common Stock - Net Assets Trend (2013–2024)
This chart illustrates how Senseonics Holdings, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Senseonics Holdings, Inc. Common Stock.
Annual Net Assets for Senseonics Holdings, Inc. Common Stock (2013–2024)
The table below shows the annual net assets of Senseonics Holdings, Inc. Common Stock from 2013 to 2024. Also explore SENS shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-16.55 Million | -146.25% |
| 2023-12-31 | $35.80 Million | +1489.60% |
| 2022-12-31 | $-2.58 Million | +98.61% |
| 2021-12-31 | $-185.53 Million | -28.77% |
| 2020-12-31 | $-144.08 Million | -1565.89% |
| 2019-12-31 | $-8.65 Million | -112.14% |
| 2018-12-31 | $71.26 Million | +880.61% |
| 2017-12-31 | $7.27 Million | +249.01% |
| 2016-12-31 | $-4.88 Million | +49.71% |
| 2015-12-31 | $-9.70 Million | -222.55% |
| 2014-12-31 | $7.91 Million | +111649.75% |
| 2013-12-31 | $7.08K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Senseonics Holdings, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94787108100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $595.00K | % |
| Other Components | $930.72 Million | % |
| Total Equity | $-16.55 Million | 100.00% |
Senseonics Holdings, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Senseonics Holdings, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aviva PLC
LSE:AV
|
$259.11 Million |
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
$259.16 Million |
|
Meter Instruments Co. Ltd
SHE:301006
|
$259.25 Million |
|
Bank Ochrony Środowiska SA
WAR:BOS
|
$259.28 Million |
|
Westwing Group AG
F:WEW
|
$259.02 Million |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
$258.96 Million |
|
Falcon's Beyond Global, Inc. Class A Common Stock
NASDAQ:FBYD
|
$258.87 Million |
|
M3-Brigade Acquisition V Corp. Units
NASDAQ:MBAVU
|
$258.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Senseonics Holdings, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,796,000 to -16,555,000, a change of -52,351,000 (-146.2%).
- Net loss of 78,616,000 reduced equity.
- New share issuances of 18,364,000 increased equity.
- Other comprehensive income increased equity by 11,000.
- Other factors increased equity by 7,890,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-78.62 Million | -474.88% |
| Share Issuances | $18.36 Million | +110.93% |
| Other Comprehensive Income | $11.00K | +0.07% |
| Other Changes | $7.89 Million | +47.66% |
| Total Change | $- | -146.25% |
Book Value vs Market Value Analysis
This analysis compares Senseonics Holdings, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.00 | $6.34 | x |
| 2014-12-31 | $1.73 | $6.34 | x |
| 2015-12-31 | $-2.12 | $6.34 | x |
| 2016-12-31 | $-1.09 | $6.34 | x |
| 2017-12-31 | $1.25 | $6.34 | x |
| 2018-12-31 | $9.05 | $6.34 | x |
| 2019-12-31 | $-0.92 | $6.34 | x |
| 2020-12-31 | $-12.64 | $6.34 | x |
| 2021-12-31 | $-8.79 | $6.34 | x |
| 2022-12-31 | $-0.08 | $6.34 | x |
| 2023-12-31 | $1.26 | $6.34 | x |
| 2024-12-31 | $-0.53 | $6.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Senseonics Holdings, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -349.84%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-22212.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -265202.65% | -110464.71% | 1.70x | 1.41x | $-18.78 Million |
| 2014 | -238.66% | 0.00% | 0.00x | 2.53x | $-19.68 Million |
| 2015 | 0.00% | -78623.68% | 0.01x | 0.00x | $-28.91 Million |
| 2016 | 0.00% | -13231.93% | 0.01x | 0.00x | $-43.44 Million |
| 2017 | -813.28% | -927.37% | 0.14x | 6.32x | $-59.83 Million |
| 2018 | -131.87% | -496.86% | 0.12x | 2.24x | $-101.10 Million |
| 2019 | 0.00% | -542.46% | 0.16x | 0.00x | $-114.68 Million |
| 2020 | 0.00% | -3539.46% | 0.14x | 0.00x | $-160.76 Million |
| 2021 | 0.00% | -2211.88% | 0.07x | 0.00x | $-283.92 Million |
| 2022 | 0.00% | 867.16% | 0.09x | 0.00x | $142.38 Million |
| 2023 | -168.71% | -269.73% | 0.16x | 3.86x | $-63.97 Million |
| 2024 | 0.00% | -349.84% | 0.22x | 0.00x | $-76.96 Million |
Industry Comparison
This section compares Senseonics Holdings, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,687,439,673
- Average return on equity (ROE) among peers: -86.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Senseonics Holdings, Inc. Common Stock (SENS) | $78.17 Million | -265202.65% | 0.79x | $259.04 Million |
| Abbott Laboratories (ABT) | $26.81 Billion | 22.24% | 1.51x | $177.42 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $10.26 Million |
| Aethlon Medical Inc (AEMD) | $1.50 Million | -324.29% | 0.70x | $1.05 Million |
| Acutus Medical Inc (AFIB) | $-225.81 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $788.17 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $784.36K | -284.06% | 0.72x | $4.92 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $1.25 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $7.63 Million | -202.23% | 0.23x | $4.09 Million |
| Artivion Inc (AORT) | $148.69 Million | 4.92% | 0.18x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $21.33 Million | -20.34% | 0.56x | $124.69 Million |
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabet… Read more